+1 (561) 832 9277 icausa@icausa.org

2017 Fellowships

ICA USA has published the following list of Research Fellowships available for funding in 2018. 

Click this link to download a complete list of the 2019 fellowships available for funding.

For more information or individual fellowship abstracts please call ICA USA at 561-832-9277.

To have us contact you about funding a 2019 Fellowship, complete the Fellowship Inquiry Contact Form here.

Descriptions of 2019 Fellowships:

Prof. Ronit Pinkas-Kramarski, Tel-Aviv University
Targeting the interaction between ErbB receptors and nucleolin.
Funding Requested $22,000

Dr. Maya Gottfried, Meir Medical Center
Comparing the response of lung cancer cells to microvesicles derived from mesenchymal stem cells of primary versus metastatic niches.
Funding Requested $22,000

Dr. Jacob Korach, Sheba Medical Center
Biological Therapy for Ovarian Granulosa Cell Tumors with CDK4/6 inhibitors.
Funding Requested $22,000

Dr. Nir Hirshoren, Hadassah Medical Center Ein Kerem Campus
Cell-type specific methylation patterns in circulating DNA for head and neck malignancies.
Funding Requested $22,000

Prof. Ariel Munitz, Tel-Aviv University
Role of eosinophils derived-granule proteins in colorectal cancer.
Funding Requested $52,000

Dr. Einav Gross, The Hebrew University of Jerusalem
Ferritin function in cancer development. As the major iron storage protein, ferritin has been linked with iron metabolism for many years. Elevated ferritin in cancer cells may be connected to cancer progression, resistance to therapies, or poor prognosis.
Funding Requested $22,000

Dr. Irit Shefler, Meir Medical Center
Lung cancer-derived microvesicles: a mediator of mast cell activation in the tumor microenvironment.
Funding Requested $52,000

Prof. Sara Eyal, The Hebrew University of Jerusalem
Transporter-based interference of histone deacetylase inhibitors with tumor imaging.
Funding Requested $22,000

Dr. Gabi Gerlitz, Ariel University
The nuclear lamina of tumor migrating cells. Many cancer types including ovarian cancer have lost or reduced expression of Lamin A/C, a structural component of the lamina matrix that underlies the nuclear envelope in differentiated cells.
Funding Requested $22,000

Prof. Ron Apte, Ben-Gurion University of the Negev
Involvement of IL-1 in metastasis of triple negative breast cancer (TNBC).
Funding Requested $22,000

Dr. Uri Rozovski, Rabin Medical Center Beilinson Campus
The role of circRNA in the pathogenesis of chronic lymphocytic leukemia (CLL).
Funding Requested $22,000

Dr. Rony Dahan, The Weizmann Institute of Science
Therapeutic effect of FcR signaling by human anti-PD-L1 antibodies.
Funding Requested $22,000

Dr. Michael Klutstein, The Hebrew University of Jerusalem
Cancer-Testis Antigens (CTA) as Specific Markers of Tumor Cells and Mediators of Genomic Instability.
Funding Requested $22,000

Dr. Yakir Rotenberg, Hadassah Medical Center Ein Kerem Campus
Intranansal delivery of Paclitaxel /Cisplatin for treating Leptomeningeal Carcinomatosis, a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. LC occurs in approximately 5% of people with cancer and is usually terminal.
Funding Requested $52,000

Prof. Zvi Fridlender, Hadassah Medical Center Ein Kerem Campus
The impact of manipulating cancer-related neutrophils on the efficacy of chemotherapy and immunotherapy in lung cancer.
Funding Requested $22,000

Dr. Iris Gluck, Sheba Medical Center
Optimizing abstinence from smoking in head and neck cancer patients utilizing combined modality therapy.

Prof. Mery Bakhanashvili, Sheba Medical Center
The participation of p53 in mitochondrial RNA degradation.
Funding Requested $22,000

Dr. Sagi Tshori, Kaplan Medical Center
Deciphering the role of lysyl tRNA synthetase- di-adenosine tetraphosphate- Nudt2 hydrolase pathway in melanoma.
Funding Requested $22,000

Dr. Ori Wald, Hadassah Medical Center Ein Kerem Campus
Identification of Chemotherapy Induced Immune Alternations in Malignant Pleural Mesothelioma. A step towards the rational design of effective chemo-immune based combination treatments for this disease.
Funding Requested $22,000

Dr. Dinora Frismann-Morvinski, Tel-Aviv University
Identification of novel immunotherapy targets in glioblastoma.

Dr. Ido Didi Fabian, Sheba Medical Center
Electroporation for the treatment of retinoblastoma in a rabbit model.
Funding Requested $22,000

Dr. Yair Bar, Sheba Medical Center
Lung cancer ex-vivo culture as a model of combined chemo-immunotherapy treatments.
Funding Requested $22,000

Dr. Ella Evron, Kaplan Medical Center
Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Mammary Cancer.

Dr. Lior Zach, Sheba Medical Center
Biological model for MRI treatment response assessment maps (TRAM).
Funding Requested $22,000

Dr. Rinat Berenstein- Molho, Sheba Medical Center
Subtype switch between primary and recurrent breast cancer: the underlying molecular mechanism and therapeutic implications.

Dr. Emmilia Hodak, Rabin Medical Center Beilinson Campus
The genetic basis of familial mycosis fungoides (cutaneous T-cell lymphoma of the skin).
Funding Requested $22,000

Prof. Zvi Fishelson, Tel-Aviv University
Characterization of toxicity of mimetic mortalin peptides on leukemia/lymphoma cells.
Funding Requested $22,000

Prof. Natan Karin, Technion -Israel Institute of Technology
The role of CCR8+ Tregs as immune checkpoints in melanoma.
Funding Requested $22,000

Prof. Yoav Livney, Technion -Israel Institute of Technology
Novel targeted oral anti-cancer drug delivery systems based on aptamer-decorated polymeric nanovehicles.
Funding Requested $22,000

Dr. Achinoam Lev-Sagie, Hadassah Mt. Scopus Hospital
CO2 Laser therapy for the treatment of genitourinary syndrome of menopause in patients with breast cancer.

Dr. Neomi Schreuer, Haifa University
Feasibility of an occupational therapy intervention to improve participation in meaningful activities among women with breast cancer.

Dr. Noga Ron-Harel, Technion-Israel Institute of Technology
Overcoming cellular metabolic hurdles to augment anticancer T cell response in the aged.
Funding Requested $22,000

Dr. Rena Pollack, Hadassah Medical Center Ein Kerem Campus
Early Identification of Patients at Risk for the Development of Immune Checkpoint Inhibitor-Induced Endocrine Dysfunction.
Funding Requested $22,000

Dr. Limor Broday, Tel-Aviv University
Modeling the EML4-ALK oncogene in C. elegans.
Funding Requested $22,000

Dr. Ariel Shimoni-Sebag, Sheba Medical Center
A new approach to pancreatic cancer: sensitizing tumors to radiation therapy through manipulation of metabolic pathways.
Funding Requested $22,000

Dr. Yishai Ofran, Rambam Health Care Campus
Phase II prospective multicenter study, to select patients with predictive good outcome out of intermediate risk acute myeloid leukemia patients, according to the results of bone marrow by the fifth day of induction and identification of the unique molecules.

Dr. Moran Gadat, Sheba Medical Center
Characterization of quantity and clonality of Tumor Infiltrating Lymphocytes in different subtypes of Renal Cell Carcinoma and association with development of metastases
Funding Requested $22,000

Dr. Guy Lahat, Tel Aviv Sourasky Medical Center
Omental Fat- Exosomes Promote Gastric Cancer Aggressiveness through Oncostatin-M: A Potential Novel Mechanism of Peritoneal Metastasis.
Funding Requested $22,000

Dr. Naomi Pode Shakked, Sheba Medical Center
Genetic engineering based novel therapeutic approaches against Wilms’ tumor.
Funding Requested $52,000

Dr. Dalit Barkan, Haifa University
Promoting tumor dormancy of breast cancer cells by inducing their reversion to a normal-like phenotype.
Funding Requested $22,000

Dr. Dalit Modan, Sheba Medical Center
Obesity, depression, and chronic stress in survivors of childhood cancer.
Funding Requested $22,000

Abstracts Available as of 1/15/2019

For more information on fellowship funding please call our office at (561) 832-9277.